# Outcomes of Cannabis Use in Trauma-Focused PTSD and SUD Treatment > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-use-trauma-focused-treatment-ptsd-sud-outcomes/ > **Published:** 2026-03-13T13:16:48-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:58:52-04:00 > **Clinical Summary:** Explore cannabis use trauma-focused treatment PTSD SUD outcomes and evidence supporting effective care for co-occurring PTSD and substance use disorders. --- #### Clinical Takeaway People with PTSD and co-occurring substance use disorders who also use cannabis can still benefit meaningfully from trauma-focused treatments. Clinicians should not withhold or delay evidence-based PTSD care based on a patient’s cannabis use status. ### #5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data. **Citation:** Hill Melanie L et al. *Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.* Journal of [anxiety disorders](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/). 2024. PMID: 38266511. **Study type:** Meta-Analysis, Journal Article, Research Support, N.I.H., Extramural  |  **Topic area:** Anxiety & PTSD  |  **CED Score:** 12 Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2 Why This Matters This meta-analysis addresses a critical clinical gap by examining whether evidence-based trauma-focused treatments remain efficacious in patients with co-occurring [PTSD and cannabis](https://cedclinic.com/cannabis-use-anxiety-young-sexual-minority-women/) use, a population frequently excluded from efficacy trials and presenting major treatment challenges in routine practice. The findings have direct implications for treatment selection and patient counseling, as they clarify whether cannabis use should alter treatment approaches or expectations for PTSD+SUD populations. Understanding these efficacy differentials can optimize resource allocation and improve outcomes in the substantial proportion of trauma-exposed individuals who present with polysubstance use patterns. **Quality Gate Alerts:** - Preclinical only **Abstract:** High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use. Clinical Perspective While this individual patient meta-analysis from Project Harmony offers valuable real-world insights into how cannabis use affects trauma-focused treatment outcomes in people with comorbid PTSD and substance use disorders, several important limitations warrant careful interpretation. The analysis draws from a subset of only four RCTs embedded within a larger 36-trial dataset, which may limit statistical power and generalizability compared to the full cohort, and the meta-analytic approach cannot fully account for unmeasured confounders such as cannabis potency, frequency of use, timing relative to treatment, or whether cannabis served primarily as self-medication versus independent substance use. Additionally, the heterogeneity of trauma-focused treatments and baseline PTSD/SUD presentations across studies, combined with varying definitions and measurement of cannabis use, creates substantial clinical complexity that aggregate analyses may obscure. Clinically, these findings should prompt individualized assessment of cannabis use patterns during [PTSD treatment](https://cedclinic.com/cannabis-and-ptsd-treatment-memory-loss-benefits/) rather than categorical exclusion, while recognizing that active cannabis use may complicate engagement with  |   |  Further Reading Research Digest[AM Policy Update: March 11, 2026](https://cedclinic.com/dea-rescheduling-marijuana-march-11-2026/) Cannabis Policy Wire[Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I](https://cedclinic.com/dea-temporary-placement-schedule-i-n-desethyl-isotonitazene/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/38266511/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11138203/)[DOI ↗](https://doi.org/10.1016/j.janxdis.2024.102827) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabinoid Clinical Trials: PTSD and Substance Use Disorder](https://cedclinic.com/cannabis-use-trauma-focused-treatment-ptsd-sud-outcomes/) Detailed analysis of cannabinoid [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) focusing on PTSD and substance use disorder co-treatment outcomes. [Read More](https://cedclinic.com/cannabis-use-trauma-focused-treatment-ptsd-sud-outcomes/) [Cannabis in PTSD Treatment: Meta-Analysis of Trauma-Focused Care](https://cedclinic.com/cannabis-use-ptsd-treatment-outcomes-meta-analysis/) Meta-analysis exploring the role of cannabis in trauma-focused [PTSD treatment](https://cedclinic.com/cannabis-and-ptsd-treatment-memory-loss-benefits/) effectiveness and patient outcomes. [Explore Study](https://cedclinic.com/cannabis-use-ptsd-treatment-outcomes-meta-analysis/) [Clinical Evidence on Cannabis Use and Trauma-Focused Treatment for PTSD and Substance Use](https://cedclinic.com/cannabis-use-trauma-focused-treatment-ptsd-sud-evidence/) Comprehensive review of clinical evidence regarding cannabis use impact on trauma-focused treatment for PTSD and substance use disorders. [Learn More](https://cedclinic.com/cannabis-use-trauma-focused-treatment-ptsd-sud-evidence/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Outcomes%20of%20Cannabis%20Use%20in%20Trauma-Focused%20PTSD%20and%20SUD%20Treatment&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-use-trauma-focused-treatment-ptsd-sud-outcomes%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-use-trauma-focused-treatment-ptsd-sud-outcomes%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Outcomes%20of%20Cannabis%20Use%20in%20Trauma-Focused%20PTSD%20and%20SUD%20Treatment%20https%3A%2F%2Fcedclinic.com%2Fcannabis-use-trauma-focused-treatment-ptsd-sud-outcomes%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).